Nextech Invest is an investment fund managing more than $594 billion ran by Marco Weibel. There are currently 13 companies in Mr. Weibel’s portfolio. The largest investments include Revolution Medicines Inc and Tyra Biosciences Inc, together worth $309 billion.
As of 7th August 2024, Nextech Invest’s top holding is 6,296,740 shares of Revolution Medicines Inc currently worth over $244 billion and making up 41.1% of the portfolio value.
Relative to the number of outstanding shares of Revolution Medicines Inc, Nextech Invest owns more than approximately 0.1% of the company.
In addition, the fund holds 4,055,861 shares of Tyra Biosciences Inc worth $64.9 billion.
The third-largest holding is Tango Therapeutics Inc worth $47.5 billion and the next is Cargo Therapeutics Inc worth $43.4 billion, with 2,642,502 shares owned.
Currently, Nextech Invest's portfolio is worth at least $594 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Nextech Invest office and employees reside in Zurich, Switzerland. According to the last 13-F report filed with the SEC, Marco Weibel serves as the Chief Financial Officer at Nextech Invest.
In the most recent 13F filing, Nextech Invest revealed that it had opened a new position in
Context Therapeutics Inc and bought 7,419,355 shares worth $14.9 billion.
The investment fund also strengthened its position in Mersana Therapeutics Inc by buying
5,669,825 additional shares.
This makes their stake in Mersana Therapeutics Inc total 9,526,146 shares worth $19.1 billion.
Mersana Therapeutics Inc soared 3.1% in the past year.
The two most similar investment funds to Nextech Invest are Sendero Wealth Management and Bluesky Wealth Advisors. They manage $594 billion and $594 billion respectively.
Nextech Invest’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 67.8% of
the total portfolio value.
The fund focuses on investments in the United States as
46.2% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.04 billion.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Revolution Medicines Inc |
No change
6,296,740
|
$244,376,479,000 | 41.11% |
| Tyra Biosciences Inc |
No change
4,055,861
|
$64,853,217,000 | 10.91% |
| Tango Therapeutics Inc |
No change
5,533,980
|
$47,481,548,000 | 7.99% |
| Cargo Therapeutics Inc |
No change
2,642,502
|
$43,389,883,000 | 7.30% |
| Arvinas Inc |
No change
1,408,394
|
$37,491,448,000 | 6.31% |
| Oric Pharmaceuticals, Inc. |
No change
5,285,714
|
$37,369,998,000 | 6.29% |
| Relay Therapeutics, Inc. |
No change
3,846,409
|
$25,078,587,000 | 4.22% |
| Cullinan Oncology, LLC |
No change
1,221,145
|
$21,296,769,000 | 3.58% |
| Mersana Therapeutics Inc |
147.03%
9,526,146
|
$19,147,553,000 | 3.22% |
| Silence Therapeutics plc |
No change
952,400
|
$18,095,600,000 | 3.04% |
| Ars Pharmaceuticals Inc |
No change
1,910,029
|
$16,254,347,000 | 2.73% |
| Context Therapeutics Inc |
Opened
7,419,355
|
$14,875,807,000 | 2.50% |
| Boundless Bio Inc |
No change
1,228,069
|
$4,752,627,000 | 0.80% |
| No transactions found | |||
| Showing first 500 out of 13 holdings | |||